Incyte‘s Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the company’s Board of Directors, effective immediately. Additionally, Lead Independent Director Julian Baker has been elected Chairman of the Board of Directors.

Meury succeeds Hervé Hoppenot, who will retire from the company after 11 years of service. Hoppenot will serve as an advisor to the CEO and will remain a member of the Board through the end of the year for a smooth transition. 

Meury is an enterprise leader with expertise in organizational strategy, pipeline, and commercial execution and capital allocation. He most recently served as CEO of Anthos Therapeutics, where he successfully scaled the company for its next stage of growth. 

Before that, Meury was CEO of Karuna Therapeutics, leading its transition into a fully integrated R&D and commercial organization. Prior to Karuna, Meury spent over two decades at Allergan, serving as Chief Commercial Officer.

“I am honored to join Incyte at this pivotal moment and thank Hervé for his support during this transition,” said Meury. “Incyte’s track record for discovering innovative treatments for complex problems in human health is outstanding. My priority is to build upon our exceptional R&D and commercial capabilities to accelerate new product flow, drive sustainable growth and create value for all stakeholders. I look forward to working with the Incyte team to continue to grow the company for enduring success.”